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ABSTRACT 
Despite the significant biological, behavioural and management differences between 
ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast, they share a great 
many morphological and molecular similarities. Differentiation of these two different 
lesions in breast pathological diagnosis is typically based on the presence of an intact 
barrier between the malignant epithelial cells and stroma, namely the myoepithelial cell 
(MEC) layer and surrounding basement membrane (BM). Despite being robust diagnostic 
criteria, the identification of MECs and BM to differentiate in situ from invasive carcinoma 
is not always straightforward. The MEC layer around DCIS may be interrupted and/or 
show an altered immunoprofile. MECs may be absent in some benign locally infiltrative 
lesions such as microglandular adenosis and infiltrating epitheliosis, and occasionally in 
non-infiltrative lesions such as apocrine change, and in these contexts this does not 
denote malignancy or invasive disease with metastatic potential. MECs may be also 
absent around some malignant lesions such as papillary carcinomas yet they behave in 
an indolent fashion akin to some DCIS. In Paget’s disease, malignant mammary 
epithelial cells extend anteriorly from the ducts to infiltrate the epidermis of the nipple 
but do not usually infiltrate through the basement membrane into the dermis. 
Conversely, BM-like material can be seen around invasive carcinoma cells and around 
metastatic tumour cell deposits. Here, we review the role of MECs and BM in breast 
pathology and highlight potential clinical implications. 
  
INTRODUCTION 
Ductal carcinoma in situ (DCIS) of the breast is defined as a proliferation of malignant 
epithelial cells confined to the ducto-lobular system of the breast without evidence of 
stromal invasion [1, 2]. Invasion is defined morphologically, as in other organ sites, by 
the absence, or breaching, of the basement membrane (BM) barrier between the 
malignant epithelial cells and surrounding stroma. In the breast there is an additional 
myoepithelial cell (MEC) layer between the epithelium and the basement membrane. At 
the molecular level, DCIS progresses to invasive carcinoma when malignant cells acquire 
the invasive phenotype [1, 3] that is the capability to infiltrate through both the 
myoepithelial and basement membrane layers. Because of challenges and limitations in 
identifying BM components using immunocytochemistry (IHC), the MEC layer has gained 
importance because of the greater simplicity of its identification immunohistochemically 
and is thus used as a surrogate marker for invasion through the BM. The loss of the MEC 
layer in breast pathology has become a key criteria for differentiating non-invasive from 
invasive disease implying, possibly incorrectly in some contexts, direct exposure of the 
malignant epithelial cells to the stroma and a subsequent ability to infiltrate and 
metastasize. 
  
Understanding the events that lead to invasiveness and the role of MECs and BM is 
crucial in improving diagnosis and management of various breast lesions. This review 
addresses the features and roles of MECs and BM in the understanding and diagnosis of 
breast lesions, with an emphasis on DCIS, and highlights the morphological use of 
specific features for differentiating benign from malignant lesions and in situ from 
invasive disease that have significant management implications. 
 
Features of DCIS progression to invasive carcinoma 
During progression from in situ to invasive disease interactions between intraductal 
malignant cells and peripheral MECs, which are thought to act as a ‘gatekeeper’ exerting 
tumour suppressive effects [4], take place leading to loss of MECs unleashing the 
progression to invasive disease [5, 6]. Molecular studies of DCIS and invasive breast 
cancer (IBC) suggest that this progression is not only driven by genomic aberrations in 
the malignant cells but also a result of complex processes involving interactions and 
cross talks of tumour cells with the surrounding stromal environment including BM, 
stromal cells, vascular spaces and immune cells [7-9] (Figure 1). In fact the process of 
progression to invasive disease is multifactorial and complexity. It is thought that the 
activity of proteolytic proteins secreted by the malignant cells to breach the BM and 
surrounding stroma is sufficient to explain progression [9] however; results of clinical 
trials of inhibitors of proteolytic enzymes to suppress tumour progression have not been 
promising [10]. In view of the limited success in identifying genetic aberrations in the 
malignant cells of DCIS that can predict invasion, despite all previous efforts, we believe 
that further understanding the role of the microenvironment and its interaction with 
DCIS cells may help in deciphering this complex process of invasion with the potential of 
improving patient management. 
Characterisation of DCIS-associated myoepithelial cells 
MECs surround both normal terminal duct lobular units and larger ducts as well as 
precancerous (in situ) lesions of the breast, forming a natural barrier and in the latter 
situation separating the abnormally proliferating epithelial (luminal) cells from the 
surrounding various stromal elements. It has been postulated that disruption of this 
barrier is required for tumour invasion and metastasis [11]. 
Loss of physical barrier 
MECs surrounding DCIS show some morphological differences to normal breast MECs 
and there is evidence to indicate that DCIS-derived MECs lose the power to polarise 
luminal epithelial cells [12]. Interestingly, discontinuity in expression of MEC markers in 
the absence of microinvasion of tumour cells into the surrounding stroma has been 
observed, raising the possibility that this could be the primary event which precedes 
tumour invasion [13]. Such interruption in the MEC layer integrity may be due to 
mechanical factors, immune reaction or loss of cellular renewal capacity [11]. The loss of 
tumour suppressor control on the epithelial cells facing these interrupted MECs has been 
supported through the analysis of the genetic and IHC features of cell clusters overlying 
focally disrupted MECs [9, 11].  
Tumour suppressor function 
MECs have natural tumour suppressor functions, including maintenance of the BM and 
epithelial cell polarity [14] and express several tumour suppressor proteins such as p63, 
p73, 14-3-3-s, Maspin, WT1, and laminin 1. MECs also exhibit many other anti-
tumourigenic properties, such as inhibition of the growth of breast cancer cells by 
inducing a G2/M cell cycle arrest, inhibiting tumour cell invasion, and lowering 
angiogenesis by paracrine control [15, 16]. Evolving experimental evidence indicates 
that their tumour-suppressive phenotype may partly be achieved by secreting protease 
inhibitors and downregulating matrix metalloproteinases [4]. MECs also express several 
ECM structural proteins and accumulate ECM rather than degrade it [17]. MECs 
participate in BM production by expression and deposition of fibronectin, collagen IV and 
laminins. They also have BM receptors, including integrins, which mediate cell–BM 
attachment and occasionally cell–to-cell interactions [18].  
 
At the molecular level, it has been shown that DCIS-associated MECs have molecular, 
genetic, and epigenetic differences from MECs in normal breast tissue [19, 20]. These 
changes include downregulation of genes that control normal MEC functions and 
upregulation of genes for chemokines that enhance epithelial cell proliferation, 
migration, and invasion [21, 22]. Allinen and colleagues examined the microenvironment 
of normal and cancerous breast tissue and found that MECs in association with DCIS 
lesions exhibited the most abundant gene expression changes of all the 
microenvironmental cell types [20], although the predictive and functional relevance of 
these changes per se are not certain. Other authors have identified specific differences in 
gene expression between normal and DCIS-associated MECs such as increased lysyl 
oxidase (LOX) [23] and neuropillin 1 [24].  
 
It has been noted that the sensitivity of some MEC markers is lower in DCIS-associated 
MECs than in normal MECs, and this observation should be taken into consideration 
when selecting MEC markers to distinguish in situ from IBC [21]. A summary of 
biomarkers used to visualise MECs in routine diagnostic practice are included in Table 1. 
Calponin, for instance, is an integral component of α-smooth muscle actin (SMA) and its 
down-regulation is consistent with compromised MECs. Maspin is one of the most 
important tumour suppressors secreted by MECs and inhibits tumourigenesis, tumour 
cell migration, angiogenesis, and metastatic spread [25]. Maspin is secreted in large 
quantities by the normal MECs, while DCIS-associated MECs do not secrete it [26]. MECs 
secret laminin 1, which is a major component of the BM structure and plays a crucial role 
in the polarity of epithelial cells within the ducts. MECs associated with DCIS show 
deficient laminin 1 deposition and hence loss of cellular polarity and differentiation 
facilitating tumour invasion [12, 27]. MECs surrounding malignant cells also express 
elevated integrin αvβ6, which has been shown to promote tumour proliferation and 
invasion through activation of TGF-β and MMP9 [28].  
 
MECs isolated from DCIS have been reported to show gene expression and epigenetic 
changes when compared to MECs isolated from normal breast tissue [19, 20] but no 
study has been able to demonstrate significant differences between MEC marker 
expression in DCIS with or without associated invasive carcinoma. Exploring such 
differences is clearly clinically important due to their potential as biomarkers of invasive 
progression. 
Observed effects of lack of MECs on epithelial proliferative breast lesions 
Despite the documented role of MECs in the progression of DCIS to invasive disease and 
the application of MEC IHC marker by pathologists to differentiate in situ from invasive 
tumours in routine practice, well recognised exceptions exist and potentially challenge 
this dogma, which if not recognised can potentially lead to incorrect classification of a 
condition as an invasive carcinoma. The biologically unexplained phenomenon of the 
absence of peripheral MEC in lesions conventionally regarded as non-invasive, or even 
non-neoplastic, is uncommonly observed in breast histopathology. Microglandular 
adenosis (MGA) and the rare entity of so called “infiltrating epitheliosis” are two 
examples of non-malignant breast lesions that lack peripheral MECs and show an 
infiltrative growth pattern [29-32].  
 
MGA shows infiltrating single-layer glands surrounded by a distinct well-developed layer 
of BM but lack a MEC layer. Cells of MGA show an immunophenotype that is different 
from hyperplastic epithelial cells in other breast lesions; they lack oestrogen receptor 
expression and show diffuse nuclear staining of S100 protein. Shared clonal driver 
mutations between uncommon cases with MGA and synchronous invasive carcinoma, 
suggestive of a precursor relationship, have been reported [33, 34]. Although atypia and 
carcinoma can arise from MGA, no metastasis has been reported in cases of pure MGA, 
which is the unequivocal hallmark, and key clinical relevance, of invasive disease. 
However, the absence of peripheral MECs poses a diagnostic challenge when the 
proliferating cells also show cytonuclear atypia and it can be extremely difficult to 
differentiate atypical MGA from invasive carcinoma. Indeed distinction of atypical MGA 
from some specific invasive carcinoma sub-types, such as acinic cell carcinoma, may 
occasionally be impossible in routine practice. It has been reported that BM is present in 
MGA but absent in acinic cell carcinoma [35], admittedly accepting that BM stains are 
capricious and difficult to interpret. In addition, the infiltrative nature and morphology of 
MGA suggests that its BM is produced by the proliferating cells, rather than being a 
native BM. 
 
Infiltrating epitheliosis is another example of a hyperplasic but seemingly benign 
epithelial lesion that shows an infiltrative growth pattern with focal absence of MECs. 
This lesion, originally described by Azzopardi, is described using his original criteria as a 
lesion that mimics carcinoma [36]. It is considered to be related to radial scar/complex 
sclerosing lesions [36] and sometimes with sclerosed papillary lesions [37]. MECs are 
mainly lost at the periphery of an infiltrative epitheliosis lesion with frequent 
preservation at the epithelial-stroma interface in the centre. Interestingly, MECs may be 
demonstrated in the proximal part of a duct but completely absent at the distal part 
where the infiltrative pattern becomes more obvious. Unlike MGA, in infiltrating 
epitheliosis there is no evidence of a thickened BM around areas lacking MECs.  
 
A recent study has argued that infiltrative epitheliosis is neoplastic rather than 
hyperplastic, based on the frequent presence of PIK3CA mutations [32]. This study also 
identified shared clonal mutations in a case of infiltrating epitheliosis with synchronous 
micropapillary DCIS and adenosquamous carcinoma, again suggesting possible precursor 
status. Given that loss of MECs has been reported in around 20% of complex sclerosing 
lesions/radial scars, and these have a risk of breast cancer of only 1.5-2x above the 
general population, the frequency of such progression is likely to be rare (and currently 
unknown).  
 
The inability to identify MECs using traditional markers in the context of complex 
sclerosing lesions may indicate phenotypic alterations in the MECs and a complex 
interaction between the proliferating epithelial cells and MECs rather than their 
mechanical disappearance in such cases. In addition, a lack of MECs in epithelial 
displacement/seeding after needling procedures, such as fine needle aspiration cytology, 
core biopsy or localisation/guidewire wire insertion, can be seen in association with both 
benign and malignant lesions and is not used as a criteria for the diagnosis of invasion, 
albeit that its clinical significance is somewhat unclear [38]. 
 
Intraductal papilloma is a benign entity typically showing an intact layer of MECs at the 
epithelial-stroma interface [39]. However, a focal loss of MECs as demonstrated 
immunohistochemically can be seen, particularly in areas showing epithelial hyperplasia 
or when the proliferating epithelial cells show prominent apocrine differentiation [40, 
41]. Infiltrative syringomatous tumour of the nipple is another controversial benign 
lesion characterised by lack of peripheral MECs together with an infiltrative growth 
pattern of glands and tubules mimicking tubular carcinoma or low grade adenosquamous 
carcinoma [42]. However, MEC IHC in this setting often highlights an outer layer of cells 
of the tubules in this lesion, which could be interpreted as retention of MECs.  Other rare 
examples of benign breast lesions featuring loss of peripheral MECs exist. We and others 
have observed this phenomenon in rare cases of fibroadenoma that lacked MECs focally 
at the epithelial/stroma interface.  
 
Some apocrine lesions without MECs may be seen, as described by Cserni who noted 
that lack of MECs in apocrine glands of the breast does not necessarily imply malignancy 
[43]. He described some benign apocrine papillary lesions of the breast lacking, or 
virtually lacking, MECs, a potential pitfall that should not be diagnosed as malignancy 
[41]. Five cases of encapsulated apocrine papillary carcinoma of the breast were 
described by Seal et al. [44], with key histological features similar to those of classical 
encapsulated papillary carcinoma (EPC) including an absence of MECs both within the 
papillary structures and at the periphery. Cases were of pure apocrine appearance 
cytologically with variable degrees of atypia and mitotic activity. All lacked evidence of 
true invasion of tissue outside of the lesion and all had an indolent behaviour. 
 
This collection of benign breast lesions indicates that the absence of MECs does not 
automatically indicate malignancy and/or invasion but their absence is sometimes 
associated with an infiltrative growth pattern. This may represent molecular changes in 
the proliferating epithelial cells that drive disappearance of peripheral MECs with focal 
infiltration of the adjacent stroma, but such changes are still not sufficient for a fully 
malignant invasive phenotype. 
 
EPC lacks peripheral MECs in approximately 80% of cases, however, their behaviour is 
sufficiently indolent that it is widely considered as a lesion equivalent to in situ disease 
[45, 46]. Pure EPC does not show a conventional infiltrative pattern of the stroma 
characteristic of IBC, indicating that the absence of MECs in these tumours per se does 
not drive the usual pattern of invasion seen in IBC. Solid papillary carcinoma (SPC) is 
another example of a malignant papillary lesion that may lack peripheral MECs but 
behaves in an indolent fashion similar to DCIS [47, 48]. Thus the absence of MECs does 
not per se imply that the lesion has acquired an invasive behaviour akin to conventional 
IBC even if it has acquired the in situ carcinoma characteristics of hyper-proliferation and 
cellular atypia [49].  
 
Another exception to the role of peripheral MECs in preventing invasion in in situ breast 
lesions (i.e. DCIS) is Paget’s disease [50]. In Paget’s disease, the malignant mammary 
epithelial cells escape their native environment and the confinement of the peripheral 
MECs and BM and infiltrate and populate the epidermis of the nipple adjacent to the 
involved mammary duct opening. Despite an absence of MECs and the native ducto-
lobular basement membrane, they remain confined to the epidermis and the majority do 
not invade the underlying dermis or stromal tissue. This pattern indicates that MECs and 
native BM of the ducto-lobular system are not the only barrier to invasion in DCIS and 
implies that some as yet unknown tumour intrinsic factors are required for the 
progression from in situ to invasion. In addition, the surrounding stromal environment 
(stromal fibroblasts, immune cells and associated vasculature) could limit neoplastic cell 
spread. 
Basement membrane and its role in the invasion process 
The BM surrounding breast ducts is an essential barrier, formed mainly of collagen type 
IV and laminin 1, along with some proteoglycans [51]. This layer is deposited by 
epithelial, myoepithelial and stromal cells and plays key roles in homeostasis of normal 
architecture and physiology [51, 52]. It must be remembered and emphasised that the 
fundamental and original definition of invasive carcinoma is based on penetration 
through the BM and establishment of growth within the stroma [53]. So, is the BM a 
rate-limiting barrier for invasion? BMs are conceived to form a protective hurdle against 
primary infiltration of the surrounding stroma by malignant epithelial cells, and invasion 
of the BM has been reported as sufficient for breast cancer cells to develop a stable 
metastatic phenotype [54].  
Although focal disruptions in the MEC layer can be observed in DCIS, the surrounding BM 
is typically intact and continuous and can be used to indicate the in situ nature of the 
lesion [9]. However, in the clinical setting it is often not simple; differentiating native BM 
surrounding the ducto-lobular system from reactive BM around some invasive lesions 
may be problematic. EPC shows a peripheral thick capsule/thickened BM-like structure 
which was interpreted as an evidence of the in situ nature of these tumours [55]. 
However, similar capsule/BM-like structure can be seen in other structures outside the 
breast suggesting that this is a reactive process rather than an expansion of the 
surrounding native BM material [56]. Conversely, BM-like structures have also been 
observed around invasive tumours even at distant metastatic sites [57-59] and may be 
particularly conspicuous in some forms such as adenoid cystic carcinoma. Other invasive 
lesions, such as squamous cell carcinoma, show basement membrane surrounding the 
invasive tumour nests [60]. Finally, some breast carcinomas show DCIS-like structures 
in the lymph nodes (revertant DCIS [61]), typically surrounded by BM-like material. BM-
like structures are also present in benign lesions such as collagenous spherulosis. In 
these the material has been found histochemically and immunohistochemically to be BM-
like, consisting of type IV collagen [62].  
 
Overall, these findings raise questions in breast histopathology about what definition of 
invasion can be used reliably in routine practice, taking into account the significant 
management implications of in situ versus invasive diagnosis. Given the subjective 
nature of interpretation of BM material staining, a panel of MEC markers is regarded as 
the gold standard for assessment of invasion in breast pathology. However, while the 
presence of MECs, as shown by IHC, has an excellent negative predictive value for 
invasion, their absence does not always indicate invasive (and thus metastatic) capacity 
of a lesion.  
 
In conclusion, the role of MECs and the BM in tumour progression is under-recognised. 
However, much remains to be clarified about the molecular mechanisms and 
physiological roles of MECs in tumour invasion and metastasis. Further research may 
lead to the development of novel approaches for the prevention and treatment of breast 
cancer. This is of particular relevance for pre-invasive breast lesions such as DCIS, 
where evaluation of the MECs and BM may conceivably be useful targets for the 
prevention of invasive disease. At the present time, however, pathologists should be 
aware of the pitfalls of criteria used in routine practice to distinguish in situ from invasive 
disease. Although it is convenient, and often useful, to use identification of loss of MECs 
by IHC as a surrogate marker of invasion it must be remembered that such observations 
do not per se indicate that the BM has been breached and this alone remains the key 
definition of, and requirement for, invasion.   
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Table 1: Immunohistochemistry of myoepithelial cells and basement membrane 
MECs Markers Sensitivity Specificity Localisation Comments  
Smooth muscle 
actin (SMA)  
High Low Cytoplasmic Any cell with substantial expression of actin 
is positive for SMA (myofibroblasts and 
blood vessels). 
Sooth muscle 
myosin heavy 
chain (SMMHC)  
Good Good Cytoplasmic Less sensitive than SMA, but more specific 
and easy to interpret. 
P63 High High Nuclear Focal gaps in staining in MEC layer. 
Around 5-10% of invasive tumours, 
particularly high-grade, metaplastic and 
salivary-like carcinomas, express p63. 
Calponin  High Low Cytoplasmic Present in a subset of myofibroblasts and 
smooth muscle in blood vessels. 
H-caldesmon  Good Good Cytoplasmic MEC around ducts and lobules may not 
express H-caldesmon. 
Maspin Good Good Cytoplasmic, 
Nuclear 
Some invasive carcinomas have been 
reported as showing maspin expression. 
CD10 Good Good Cytoplasmic Rarely expressed in the tumour cells of 
invasive carcinomas and in some sarcomas. 
Less sensitive than SMA. 
Basal CKs (CK5/6, 
CK14, CK17) 
Low Low Cytoplasmic, 
Membranous 
Low sensitivity and specificity. 
Positive in carcinomas, particularly high 
grade lesions. 
p-cadherin  Good Good Cytoplasmic  No cross reactivity with other stromal cells 
and 20-40% of invasive carcinoma may show 
positivity. 
p-75  Good Low Cytoplasmic, 
Membranous 
Expressed in blood vessels, nerves, and 
epithelial/luminal cells in usual epithelial 
hyperplasia and also expressed in 5% of 
invasive carcinomas. 
S100 Low Low Cytoplasmic, 
Nuclear 
May be positive in epithelial cells and 
invasive carcinomas. 
Other MEC 
markers 
   CD109, caveolin 1, podoplanin, maspin, 
nestin, alpha 1-integrin, and 14-3-3 sigma 
(stratifin). 
Basement Membrane Markers 
Laminin  Good Good Cytoplasmic May be difficult to interpret due to 
background stromal staining but comparison 
with normal parenchyma may help. 
Collagen IV  Good Good Cytoplasmic Similar to laminin. 
 
To demonstrate myoepithelial cells (MECs), a panel-based approach of 2 or more 
immunocytochemical markers is recommended. Many departments therefore use, for 
example,  SMM and p63 in order to avoid false negative results in differentiating in situ 
from invasive lesions. Aberrant expression of MEC markers is seen in salivary gland-like 
and skin adnexal-like tumours of the breast, adenomyoepithelioma and metaplastic 
mammary carcinomas. 
  
Table 2 Non-malignant conditions associated with lack of myoepithelial cells 
(MEC) and/or basement membrane (BM) 
Lesion MEC BM Infiltrative Precursor to IBC Risk of IBC 
Microglandular adenosis Absent Present Yes Yes Unknown 
Infiltrating epitheliosis Focally 
absent 
Absent Yes Unknown Rare 
Radial scar/complex 
sclerosing lesion 
Absent 
in 20% 
Present No No 1.5-2x 
Intraductal papilloma Focally 
absent 
Present No If epithelial 
atypia is present  
2-3x 
Infiltrative 
syringomatous tumour 
of the nipple 
Absent No Yes Unknown Unknown 
Fibroadenoma Rarely 
absent 
Present No No No 
Benign apocrine, 
including papillary foci 
Absent Present No No No 
Encapsulated apocrine 
papillary carcinoma 
Absent Present
/pseud
ocapsul
e 
No Yes Higher 
than DCIS  
Encapsulated papillary 
carcinomas 
Absent in 
80% 
Present/
pseudoc
apsule 
No No Higher than 
DCIS 
Paget’s disease Absent Absent Yes Yes Unknown 
 
 
 
  
Figure Legends 
 
Figure 1: Schematic representation of normal breast terminal duct (A) and ductal 
carcinoma in situ with focus of early invasion (B). Normal ducts (A) present with 
continuous myoepithelial cell (MEC) layer (b) and surrounding continuous well-defined 
basement membrane (a). Although MECs surround both normal ducts and malignant in 
situ lesions, MECs surrounding DCIS show some morphological differences and lose the 
power to polarize epithelial cells. Changes in MEC layer continuity might be related to 
mechanical factors, immune reaction, loss of cellular renewal capacity or exogenous 
chemical influence. Stromal invasion and progression to invasive disease (c) starts with 
breaching, or absence, of MEC layer and basement membrane barriers between the 
malignant epithelial cells and surrounding stroma. Changes in the interaction between 
malignant epithelial cells and stromal microenvironment, including the extracellular 
matrix, fibroblasts and immune cells, are believed to also play a role in invasion. 
 
 
